- Home
- EPRX vs ANIX Comparison
EPRX vs ANIX Comparison
Compare EPRX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- ANIX
- Stock Information
- Founded
- EPRX 2011
- ANIX 1982
- Country
- EPRX Canada
- ANIX United States
- Employees
- EPRX 21
- ANIX N/A
- Industry
- EPRX
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- EPRX
- ANIX Health Care
- Exchange
- EPRX NYSE
- ANIX Nasdaq
- Market Cap
- EPRX 91.9M
- ANIX 106.3M
- IPO Year
- EPRX N/A
- ANIX 1987
- Fundamental
- Price
- EPRX $2.61
- ANIX $3.31
- Analyst Decision
- EPRX
- ANIX Strong Buy
- Analyst Count
- EPRX 0
- ANIX 2
- Target Price
- EPRX N/A
- ANIX $8.50
- AVG Volume (30 Days)
- EPRX 4.6K
- ANIX 61.3K
- Earning Date
- EPRX 01-01-0001
- ANIX 09-24-2024
- Dividend Yield
- EPRX N/A
- ANIX N/A
- EPS Growth
- EPRX N/A
- ANIX N/A
- EPS
- EPRX N/A
- ANIX N/A
- Revenue
- EPRX N/A
- ANIX N/A
- Revenue This Year
- EPRX N/A
- ANIX N/A
- Revenue Next Year
- EPRX N/A
- ANIX N/A
- P/E Ratio
- EPRX N/A
- ANIX N/A
- Revenue Growth
- EPRX N/A
- ANIX N/A
- 52 Week Low
- EPRX $2.39
- ANIX $2.15
- 52 Week High
- EPRX $3.50
- ANIX $5.13
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- ANIX 56.84
- Support Level
- EPRX N/A
- ANIX $3.03
- Resistance Level
- EPRX N/A
- ANIX $3.50
- Average True Range (ATR)
- EPRX 0.00
- ANIX 0.18
- MACD
- EPRX 0.00
- ANIX -0.01
- Stochastic Oscillator
- EPRX 0.00
- ANIX 63.46
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.